Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
for info, extract from an iweb notification I received recently
"Subsequently, the Demerger is expected to become effective on 30th October 2020 and the Ex-entitlement for the New Accustem shares is expected to be 2nd November 2020. However, it is not yet known when the New Accustem shares will be received. "
& may be another reason to demerge accustem from tils
Will be interesting to see how tils performs today in usa. Shorts were about 24% of volume on friday, & closing price was about £1.46. On VERY little volume pre-market is still about that level.
Innova's offering is owned by Pasaca: https://pasacacapital.com/ with numerous interests including Finance, Infrastruture, Manufacturing, Hi Tech, Entertainment & Healthcare. A partner in that organisation Ersin Sanft, co-founded Innova Strategies in 2017 (own Innova tried & tested??). Innova Strategies HQ is in Sri Lanka. Links to Pasaca & Innova's test....
https://pasacacapital.com/
https://static1.squarespace.com/static/5e8444f9372f7161749366af/t/5f252b2cb71b7012a5403a0f/1596271422787/TriedandTested+Rapid+Antigen+Test+v2.0.pdf
,
JP Morgan developed an 'algo bot' in 2017 (https://wccftech.com/jp-morgan-working-on-machine-learning-trading-bot/).
JPMorgan is Depositary Bank for the ADR Program.
Morgan Stanley hold a (small) position in tils as at 30 Jun
Common factor JPM.
Approx 18% short again yesterday, total short some 741k as at 15 October.
Something untoward??
Whimax, thought the value per share to be attributable at the time of the demerger &, therefore, that would be what the shorter has to pay the owner of the borrowed shares at that moment in time. Theoretically (don't for one minute suggest likely), if the Accustem valuation went down, the owner would have benefitted from a 'premium' payment. So, if value is established/paid at time of demerger In the event Accustem was sold, the owner of the borrowed shares would have no further rights.
I accept, the above is unlikely, but does anyone know for sure how shorting works in the current circumstance. I know shorters have to pay over dividends declared should they be short through to an ex-divi date, so using that as a guide hypothisised accordingly. Re any other news, yes that can happen at any time, but the shorters are ignoring that anyway.
In the highly unlikely event I was correct there would be a benefit to holders at the time of the split. The shorters shares would no longer exist which would mean the remaining shares increase in value.
Hopefully, failing the above, we should expect a mad scramble to close positions.
Y-Alam think the problem with the sp has been the Nasdaq listing & the adr in particular. There are other coys on AIM with multi billion £ potentential that have been at the mercy of mms, traders, etc that will only realise true value when products are validated/brought to market/bought out, that have suffered similarly to Tils (I also hold avct). Proof of the pudding will (hopefully) be Foralumab.
Whimax, I have wondered what value will be attributed to Accustem at the point of the demerger. If it is the current book value then I can see no reason why the shorters won't continue to hold through to the ex date 2 Nov. They could even continue to short until a 'true' valuation is established/notified, or news (or anticipated news) on Foralumab. Any opinion?
Unfortunately, at this moment, the 'bot' is taking the sp down https://www.nasdaq.com/market-activity/stocks/tlsa/real-time
Let's hope it has a change of mood sooner rather than later.
Whimax, agree. Posted similar sentiment in September.
Last 2 days of trading shorts had 22% & 26% of the volume. Close of play 30 September total short position was in excess of 625k shares, which was the most recorded over the previous 12 months.
Doesn't matter what happens on AIM, at the moment we are governed by the Nasdaq. Let's hope the immediate run-in to the split provides some positive action.
Has been common to several promising investments. Avacta, Tiziana, Omega, Novacyt & several other 'sound' stocks have endured same fate, but look where they are now. The options are clear, hold if you have faith in the company, sell if not, or trade the waves that will undoubtedly occur. Extreme emotions can be experienced when investing on AIM.
Both links below indicate employee:
https://www.sec.gov/Archives/edgar/data/1415016/000119312507220537/dex101.htm
https://www.nibusinessinfo.co.uk/content/defining-share-option-and-share-award-schemes
If so, are they thinking of selling?
$4.10, but on VERY small volume https://www.marketwatch.com/investing/stock/tlsa
However, it could indicate the direction of travel we could be taken today. Onward & upward, hopefully.
When suggesting the Main Market I'm not referring to the ftse 100, nor the Premium Main Market, only the Standard Main Market, where there has to be a minimum valuation of £700k.
We all know AIM is the 'wild west' & probably lacks the credibility of the Main Market. Unless there are good reasons to remain on AIM (& there are a couple) the Main Market would offer a quicker route to the Prmium Market.
For info https://www.valuethemarkets.com/2018/02/26/aim-listing-vs-standard-listing-main-market-whats-difference/